Physician

Gary R Macvicar, MD

According to 2025 Medicare claims, Gary Macvicar, MD (NPI: 1487633251) practices hematology/oncology in the Peoria, IL market, with the plurality of this provider's patient population coming from Peoria, IL. This provider's primary affiliated billing organization is ONCOLOGY-HEMATOLOGY ASSOCIATES OF CENTRAL ILLINOIS P C (NPI: 1801896063; TIN: 371331017) and primary practice location at 61615-7822. Macvicar is affiliated with the OSF Healthcare System (ACO ID: A3289), participating under the MSSP model.

Macvicar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,070 traditional Medicare patients, billed 225,991 HCPCS/CPT codes, and received $3,526,248 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,483 prescription claims across 334 beneficiaries totaling $4,487,490 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 11 claims. Open Payments data shows 38 records totaling $449,844. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,020,070 to $4,487,490. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $11,172 to $617.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	992	142,635	$1,795,111
2016	1,349	270,790	$3,214,847
2017	1,407	303,524	$3,610,160
2018	1,414	300,470	$4,035,066
2019	1,589	340,331	$5,002,694
2020	1,193	238,589	$4,079,975
2021	1,165	206,692	$3,490,702
2022	1,099	196,698	$2,967,620
2023	1,049	222,763	$2,932,335
2024	1,070	225,991	$3,526,248

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	161	1,389	$1,020,070
2016	173	1,408	$998,406
2017	215	1,665	$1,680,067
2018	239	2,244	$2,676,703
2019	252	1,981	$2,265,090
2020	237	1,958	$2,494,361
2021	278	2,184	$3,494,163
2022	273	2,459	$4,766,462
2023	292	2,362	$3,799,100
2024	334	2,483	$4,487,490

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	243	$63,314
2016	N/R	154	$30,166
2017	N/R	N/R	N/R
2018	N/R	16	$4,384
2019	N/R	38	$3,808
2020	N/R	N/R	N/R
2021	N/R	66	$5,519
2022	N/R	N/R	N/R
2023	N/R	12	$673
2024	N/R	11	$361

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	362	845	$94
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	313	600	$12
80053	Blood test, comprehensive group of blood chemicals	233	864	$10
36415	Insertion of needle into vein for collection of blood sample	246	948	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	245	965	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	44	1,127	$671,408
Xtandi	Enzalutamide	48	1,440	$637,283
Abiraterone Acetate	Abiraterone Acetate	324	10,045	$506,493
Nubeqa	Darolutamide	40	1,320	$471,899
Imbruvica	Ibrutinib	28	784	$455,539

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
K0001	Standard wheelchair	Y	N/R	11	$361

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	0	$0	N/R
Research Payments	Reported research-related payment or transfer-of-value amount.	38	$449,844	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Gary R. Macvicar, MD?

Tedicare shows public-source Medicare data for Gary R. Macvicar, MD (NPI 1487633251), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Gary R. Macvicar, MD have ACO affiliation data?

Gary R. Macvicar, MD is shown with ACO affiliation data for OSF Healthcare System (MSSP, ACO ID A3289).

What billing organization is linked to Gary R. Macvicar, MD?

Gary R. Macvicar, MD is linked to ONCOLOGY-HEMATOLOGY ASSOCIATES OF CENTRAL ILLINOIS P C (billing NPI 1801896063) in the available physician profile data.

Does Gary R. Macvicar, MD have Open Payments data?

Gary R. Macvicar, MD has 38 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.